王璐璐，1973年出生，籍貫杭州。醫(yī)藥生物技術(shù)研究所研究員，博士生導(dǎo)師。1992年考入上海醫(yī)科大學(xué)藥學(xué)專業(yè)，1996年獲學(xué)士學(xué)位。1999年在中國協(xié)和醫(yī)科大學(xué)藥劑學(xué)專業(yè)攻讀碩士學(xué)位，從事藥物靶向遞送研究。2014年在北京協(xié)和醫(yī)學(xué)院藥理學(xué)專業(yè)攻讀博士學(xué)位，從事小分子藥物機制研究。1996年進入醫(yī)藥生物技術(shù)研究所工作，1998年調(diào)入藥物研究所，2004年任助理研究員，2012年任副研究員，2021年任研究員。2022年調(diào)回醫(yī)藥生物技術(shù)研究所，從事納米生物技術(shù)研究。

長期從事納米藥物設(shè)計及作用機制研究。工作聚焦藥物的轉(zhuǎn)化性，通過生物學(xué)與藥學(xué)的結(jié)合促進新藥研究的深度、創(chuàng)新性及實用性。重點為抗代謝及抗腫瘤藥物研發(fā)。 主要工作之一為小檗堿及其衍生物的基礎(chǔ)與轉(zhuǎn)化研究，形成了從藥理機制解析—遞送系統(tǒng)構(gòu)建—臨床轉(zhuǎn)化的全程創(chuàng)新能力，作為核心骨干推動小檗堿制劑研發(fā)并獲臨床批件（CHXL1500649），推動小檗堿衍生物HTD1801進入降糖Ⅲ期臨床（CHXB2400062）。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1. Kaichao Song i#, Ling Ren i#, Xiuping Guo i#, Gang Ren i#, Yanan Sun, XiaoLian Tian, Chujuan Hu, Mingyu Pan, Quanyong Yu, Zhigang Luo, Yumei Hao, Peng Lei, Haoyang Yu, Sitong Yang, Qingbo Chen, Yuanbin Li, Shan Wang, Yingying He, Zhouguang Hui*, Wensheng Zheng*, Jiandong Jiang*, Lulu Wang*. Microbiotaresponsive oral nanoamifostine enables colorectalspecifc radioprotection and tumor immunity via gut microenvironment reprogramming. Advanced Composites and Hybrid Materials (2025) 8:432. (IF=21.8)

2. Yiyang Chen, Shuang Liang, Yuxuan Peng, Kongshuo Ma, Kaiqing Yun, Xinbo Ma , Linna Hai, Lin Mei*, Lulu Wang*, Zhaohui Wang*. Nanomaterials-enabled mRNA delivery for Cancer immunotherapy. Coordination Chemistry Reviews 543 (2025) 216945. (IF=23.5)

3. Xia Niu i#, Ge Chang i#, Ning Xu i#, Rui Li i#, Bingyu Niu, Rui Mao, Shan Wang, Guiling Li*, Jiandong Jiang*, and Lulu Wang*. Vitamin AIntegrated Cinnamaldehyde Nanoemulsion: A Nanotherapeutic Approach To Counteract Liver Fibrosis via Gut?Liver Axis Modulation. ACS Nano 2025 19(10), 10433-10451. (IF=17.6)

4. Chuchu Zhou, Rou Tang, Huajin Tan, Yige Yang, Peipei Meng, He Li, Kaichao Song, Xiaochuan Tan , Xiuping Guo, Ling Ren, Shuwang He, Ya Meng, Yumei Hao, Mingbao Lin, Yujia Zhang, Hongdong Huang*, Lulu Wang*, Wensheng Zheng*. Biomimetic Nanodisks Are Effective Against Tubulointerstitial Fibrosis via Targeting Interstitial Microenvironment. Circulation Research. 2024;135:e150. (IF=16.5)

5. Xia Niu#, Yanan Meng#, Jinjin Cui#, Rui Li, Xiao Ding, Bingyu Niu, Ge Chang, Ning Xu, Guiling Li*, Yucheng Wang*, and Lulu Wang*. Hepatic Stellate Cell- and Liver MicrobiomeSpeciffc Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis ACS Nano 2023 17 (23), 23608-23625. (IF=15.8)

6. 1. Jin-Jin Cui#, Rui Li#, Xiao-Lei Ma#, Hao-Yang Yu#, Zhi-Gang Luo#, Peng Du, Ling Ren, Xiao Ding, Xiu-Ping Guo, Wen-Sheng Zheng, Jian-Dong Jiang,* Yongsheng Che,* and Lu-Lu Wang*. Prebiotic-Based Nanoamorphous Atorvastatin Attenuates Nonalcoholic Fatty Liver Disease by Retrieving Gut and Liver Health. Small Struct 2023, 4(8):2200312. (IF=13.9)

7. Ling Ren#, Xiao-Lei Ma#, Hong-Liang Wang#, Rui Li#, Jin-Jin Cui, Peng-Ju Yan, Ya-Nan Wang, Xiao-You Yu, Peng Du, Hao-Yang Yu, Hui-Hui Guo, Rou Tang, Yong-sheng Che, Wen-Sheng Zheng*, Jian-Dong Jiang*, Lu-Lu Wang*. Prebiotic-like cyclodextrin assisted silybin on NAFLD through restoring liver and gut homeostasis. J Control Release. 2022, 348:825–840. (IF=10.5)

8. Xiao-Lin Li#, Jin-Jin Cui#, Wen-Sheng Zheng#, Jin-Lan Zhang#, Rui Li, Xiao-Lei Ma, Miao Lin, Hui-Hui Guo, Cong Li, Xiao-You Yu, Peng Du, Li-Min Zhao, Shuwang He, Pei Lan, Jian-Dong Jiang,* Yongsheng Che,* and Lu-Lu Wang*. Bicyclol Alleviates Atherosclerosis by Manipulating Gut Microbiota. Small. 2022, 18(9):2105021. (IF=13.3)

9. Yumei Hao#, Kaichao Song#, Xiaochuan Tan#, Ling Ren, Xiuping Guo, Chuchu Zhou, He Li, Jin Wen, Ya Meng, Mingbao Lin, Yujia Zhang,* Hongdong Huang,* Lulu Wang,* and Wensheng Zheng*. Reactive Oxygen Species-Responsive Polypeptide Drug Delivery System Targeted Activated Hepatic Stellate Cells to Ameliorate Liver Fibrosis. ACS Nano 2022, 16(12):20739?20757. (IF=17.1)

10. Jin-Lan Zhang#, Yu-Huan Li#, Lu-Lu Wang#, Hong-Qi Liu#, Shuai-Yao Lu#, Yong Liu, Ke Li, Bin Liu, Su-Yun Li, Feng-Min Shao, Kun Wang, Ning Sheng, Rui Li, Jin-Jin Cui, Pei-Chun Sun, Chun-Xia Ma, Bo Zhu, Zhe Wang, Yuan-Hao Wan, Shi-Shan Yu, Yongsheng Che, Chao-Yang Wang, Chen Wang, Qiangqian Zhang, Li-Min Zhao, Xiao-Zhong Peng*, Zhenshun Cheng*, Jun-Biao Chang*, Jian-Dong Jiang*. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Tar 2021, 6:414. (IF=38.1)